87 completed, 34 unknown, 17 recruiting, 16 terminated. 44 Phase 4, 43 Phase 3, 36 Phase 2, 19 Phase 1, 17 Not applicable.
Follow Meropenem: new trials by email Literature Review of Meropenem trials Research Report on Meropenem
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS) Piperacillin + Tazobactam, meropenem - Infection, Acute Kidney Injury | Phase 4 | Recruiting | Bassett Healthcare | 852 | 2026-08-17 | 2026-10-15 |
| Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria TQD3524, Meropenem for injection, Colistimethate Sodium for Injection - Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 48 | 2026-07-21 | 2026-09-04 |
| COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE meropenem, Meropenem and azithromycin combination - Typhoid Fever | Not applicable | Not yet recruiting | Iqra Asghar Ali | 94 | 2026-07-01 | 2026-06-11 |
| Cefotetan Therapy for Escherichia Coli Infections Cefotetan, Carbapenems, Beta Lactam Antibiotics - E Coli Infection, ESBL Producing E.Coli | Phase 2 | Recruiting | Oregon Health and Science University | 50 | 2026-06-26 | 2026-10-16 |
| Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia Early Discontinuation of Antibiotics, Standard Antibiotic Continuation Strategy - Febrile Neutropenia (FN), Pediatric Cancer | Phase 4 | Not yet recruiting | Hospital Universitari Vall d'Hebron Research Institute | 136 | 2026-06-01 | 2026-05-15 |
| Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria "Imipenem/cilastatin" and "Tigecycline", "colistin" and "meropenem" - MDR Bacteria | Phase 2 | Not yet recruiting | Ain Shams University | 60 | 2026-04-01 | 2026-04-13 |
| A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP Meropenem and Pralurbactam, Ceftazidime-avibactam - Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 420 | 2026-01-22 | 2026-02-17 |
| Colistin and Meropenem Versus Amikacin and Meropenem for MDR Gram Negative Bacteria Regarding Efficacy and Safety. Colistimethate sodium for injection, meropenem, Amikacin Injection and meropenem - MDR Bacteria | Phase 4 | Active not recruiting | Beni-Suef University | 100 | 2025-12-30 | 2026-07-14 |
| Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children Beta-lactam antibiotic, Beta-lactam model-informed precision dosing - Amoxicillin-clavulanate, Piperacillin-tazobactam | Phase 4 | Recruiting | University Hospital, Ghent | 58 | 2025-07-09 | 2026-09-17 |
| Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis Meropenem, Piperacillin/Tazobactam - Sepsis, Septic Shock | Phase 4 | Recruiting | Scandinavian Critical Care Trials Group | 5800 | 2025-06-26 | 2025-07-03 |
| Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP Cefepime-taniborbactam, Meropenem - Ventilator-associated Pneumonia, Hospital-acquired Pneumonia | Phase 3 | Withdrawn | Venatorx Pharmaceuticals, Inc. | 2025-06-01 | 2025-06-08 | |
| This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever Meropenem, Azithromycin + Metronidazole - Extensively Drug-Resistant Typhoid Fever, Typhoid Fever | Phase 4 | Completed | Sheikh Zayed Medical College | 90 | 2025-05-14 | 2026-03-03 |
| Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants ANT3310, Meropenem - Pharmacokinetics Study on Healthy Volunteers Adults | Phase 1 | Completed | Antabio | 26 | 2025-04-28 | 2025-10-02 |
| Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever Azithromycin, Meropenem Injection - Enteric Fever | Phase 4 | Recruiting | Indus Hospital and Health Network | 40 | 2025-04-22 | 2026-05-08 |
| Optimising TREATment for Severe Gram-Negative Bacterial Infections Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem - Bloodstream Infection, Ventilator Associated Bacterial Pneumonia | Phase 4 | Recruiting | National University of Singapore | 600 | 2025-04-21 | 2025-06-04 |
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam) - Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 80 | 2025-04-12 | 2025-07-30 |
| A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia HRS-8427, Meropenem - Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 120 | 2025-04-10 | 2026-10-22 |
| Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens Ceftolozane-Tazobactam, Meropenem - Febrile Neutropenia | Phase 4 | Recruiting | Beneficência Portuguesa de São Paulo | 55 | 2025-03-26 | 2026-09-18 |
| A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections Meropenem plus vaborbactam - Gram Negative Infections | Phase 2 | Recruiting | Menarini Group | 44 | 2025-02-18 | 2026-10-07 |
| Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections. Meropenem Injection, Ceftazidime-avibactam, Teicoplanin - Acute-On-Chronic Liver Failure | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 150 | 2025-02-10 | 2025-02-10 |
Showing 20 of 168. Sign in to see all of them.
Sepsis (24) · Bacterial Infections (11) · Infections (11) · Febrile Neutropenia (10) · Pneumonia (10) · Shock, Septic (10) · Critical Illness (8) · Bacteremia (6) · Pneumonia, Ventilator-Associated (6) · Cystic Fibrosis (5) · Neoplasms (5) · Urinary Tract Infections (5) · Enterobacteriaceae Infections (4) · Healthcare-Associated Pneumonia (4) · Typhoid Fever (4)
Pfizer (10) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (4) · King Abdul Aziz Specialist Hospital (4) · Qilu Pharmaceutical Co., Ltd. (4) · The University of Queensland (4) · Ain Shams University (3) · Antabio (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Hoffmann-La Roche (3) · Merck Sharp & Dohme LLC (3) · Rambam Health Care Campus (3) · TASK Applied Science (3) · University Hospital Tuebingen (3) · Achaogen, Inc. (2)
United States (39) · China (24) · Spain (18) · Italy (15) · Russia (13) · Hungary (12) · France (11) · Thailand (11) · Poland (10) · South Africa (10) · Bulgaria (9) · Czechia (9) · Germany (9) · Israel (9) · Romania (9)
Mical Paul, MD (3) · Issam I Raad (2) · Lynn E Connolly, MD, PhD (2) · Noa Eliakim-Raz, MD (2) · Roni Bitterman, MD (2) · Sutep Jaruratanasirikul, M.D. (2) · Sutep Jaruratanasirikul, MD (2) · A-Dong Shen, Master (1) · A.K. Deb (1) · Adam T Hill, MBCHB, MRCP, MD (1)
PMID 30061279, PMID 29912399, PMID 30221827, PMID 32602065, PMID 37700689, PMID 20594297, PMID 25155587, PMID 26289222, PMID 26755499, PMID 29456043, PMID 1444289, PMID 1482149, PMID 15031728, PMID 15276398, PMID 15840453, PMID 16304153, PMID 16531428, PMID 16640454, PMID 17135183, PMID 17846133, PMID 18095221, PMID 18788687, PMID 19095679, PMID 19237886, PMID 19384201, PMID 19398460, PMID 19588358, PMID 20561826, PMID 21142293, PMID 21440486, PMID 21730935, PMID 21788467, PMID 21862409, PMID 22147550, PMID 22194591, PMID 22530208, PMID 22692171, PMID 22839761, PMID 22955430, PMID 23074314, PMID 23153962, PMID 23254142, PMID 23318279, PMID 24080664, PMID 24429437, PMID 24657044, PMID 24731745, PMID 24768475, PMID 24982069, PMID 25072441
2016 (6), 2014 (2), 2018 (2), 2023 (2), 2005 (1), 2009 (1), 2015 (1), 2017 (1)